Possible Biomarkers for Cancer Immunotherapy.

However, the association between response and expression of PD-L1 on tumor cells did not reach statistical significance [ 14 ].

also in 111,027 other papers

In a retrospective analysis that included 58 patients with NSCLC treated with anti-PD-1/PD-L1 therapies, EGFR -mutant or ALK -positive patients showed a statistically significant shorter PFS and borderline significant lower ORR compared with EGFR wild-type and ALK -negative/unknown patients [ 42 ].

also in 11,409 other papers